Improved pharmacotherapy after revised dosing regimens of two slow-release formulations of benzylpenicillin in an Actinobacillus pleuropneumoniae infection model in pigs

Table 3 The extent of median macroscopic lesions of pneumonia, pleuritis, and thoracic adhesions

Trial	Treatment group	Extent of pneumonia (%)	Extent of pleuritis (%)	Thoracic adhesions (%)
1	ETH20-2 × 3	13 (1–27)	5 (0–16)	2 (0–15)
1	ETH20-1 × 3	12 (3–32)	9 (0–30)	0 (0–15)
1	ETH30-1 × 3	16 (3–62)	16 (3–62)	20 (0–55)
1	UPA30-1 × 3	25 (9–88)	19 (5—71)	0 (0–50)
1	Untreated	44 (39–99)	50 (30–100)	10 (3–40)
2	ETH30-2 × 5	2 (0–15)	0 (0–9)	0 (0–30)
2	UPA30-1 × 5	0 (0–29)	0 (0–28)	0 (0–45)
2	UPA30-1 × 3	1 (0–13)	1 (0–7)	0 (0–10)
2	UPA60 + UPA30-1 × 2	0 (0–2)	1 (0–5)	0 (0–2)
2	ETH30 + UPA30-1 × 3¹	1 (0–4)	0 (0–0)	0 (0–3)
2	Untreated	29 (4–40)	29 (8–45)	18 (3–65)

¹ Ethacilin vet 30 mg/kg was administered twelve hours before the first Ultrapen vet administration
Pigs were challenged with an intranasal inoculation of Actinobacillus pleuropneumoniae serotype 2 and then treated with different dosing regimens of procaine benzylpenicillin intramuscularly. The treatment group nomenclature is: the medicinal product, either procaine benzylpenicillin in a water suspension (ETH) or procaine benzylpenicillin in an oil suspension (UPA); dose in mg/kg; dose frequency (once or twice daily) and treatment duration in days. For example, ETH20-2 × 3 should read as: procaine benzylpenicillin in a water suspension 20 mg/kg bodyweight twice daily for three days

ISSN: 1751-0147